AUTHORS
Colin J. Thomas, MD, Omar Elghawy, MD2, Annapurna Saksena, MD3, Daniel Landsburg, MD4, Sunita Dwivedy Nasta, MD, MS5, Kimberly Carlton, RN6, Joshua D Brandstadter, MD,PhD,MSc7, Jordan S Carter, MD8, Elise A. Chong, MD9, Emeline R Chong, BA10, Michael R Cook, MD11, Mitchell Hughes12, Stephen J Schuster, MD13, Jakub Svoboda, MD14, Emily B. Tomasulo, DO15, Luca Paruzzo, MD16, Marco Ruella, MD17, Stefan K Barta, MD18
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, United States
3 University of Pennsylvania, Philadelphia, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 University of Pennsylvania, Philadelphia, Pennsylvania, United States
18 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
INTRODUCTION: Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) is the most common subtype of PTCL, accounting for 25% of all PTCL, representing a heterogeneous subtype not fitting other defined PTCLs. Cytotoxic marker positive PTCL-NOS (cpPTCL-NOS) refers to cases expressing cytotoxic molecules such as TIA-1, granzyme B, and/or perforin, representing about 40% of all PTCL-NOS. Worse outcomes compared to cytotoxic marker negative PTCL-NOS (cnPTCL-NOS) have been reported, though, reports of indolent cpPTCL-NOS cases have also been made. Immune dysregulation and frequent epigenetic mutations have been described in cpPTCL-NOS pts; however, little is still reported on clinical features and outcomes of this cohort of pts.
METHODS: A retrospective study of cpPTCL-NOS and cnPTCL-NOS pts diagnosed after January 1st, 2012, was conducted at the Abramson Cancer Center, University of Pennsylvania. Pathologic diagnosis (dx) had to be consistent with PTCL-NOS, ruled out for other PTCLs. cnPTCL-NOS required negative immunohistochemistry (IHC) staining for ≥ 2 cytotoxic markers. cpPTCL-NOS required positive IHC staining for ≥ 1 of the cytotoxic markers. Pts were excluded if cytotoxic markers were not assessed. Fisher’s exact test, Wilcoxon rank-sum test and multivariable Cox proportional hazards regression were used for statistical significance.
RESULTS: A total of 42 cpPTCL-NOS and 41 cnPTCL-NOS pts were identified. Baseline clinical characteristics were largely comparable, including sex, age at diagnosis, race, advanced stage, extranodal disease, elevated LDH, EBER positivity, autoimmune disease, and prevalence of low Ki-67 (≤30%). Compared with cnPTCL-NOS, cpPTCL-NOS pts were significantly more likely to have synchronous or metachronous B-cell malignancies (23.8% vs 4.9%, p<0.04) and to develop lymphoma-associated HLH (31.0% vs 7.3%, p<0.05).
Regarding cpPTCL-NOS immunophenotype, 31.7% were CD4-/CD8+, 24.4% CD4-/CD8-, 19.5% CD4+/CD8+, and 24.4% CD4+/CD8-. Disease associated variants (DAVs) were assessed in 25 cpPTCL-NOS pts and 21 cnPTCL-NOS pts: TET2 (24% vs 19%), DNMT3A (16% vs 9.5%), STAT3 (12% vs 0%), TP53 (8% vs 28.6%), FAS (8% vs 0%), TERT2 (8% vs 0%), SOCS1 (0% vs 9.5%).
Frontline treatments and utilization of autologous or allogeneic HSCT were comparable between cpPTCL-NOS and cnPTCL-NOS cohorts; ORR/CRR to CHOP-like and CHOEP/EPOCH regimens were similar: 75%/55% vs 79%/62% and 79%/36% vs 81%/37%. Regarding ORR for R/R treatments, pralatrexate was 57% (4/7 [2 PR, 2 CR)) vs 28.6% (2/7 [1 PR, 1 CR]), romidepsin 14.3% (1/7 [1 PR]) vs 28.6% (2/7 [1 PR, 1 CR]), duvelisib 50% (2/4 [1 PR, 1 CR]) vs 60% (6/10 [3 PR, 3 CR]), BV 60% (3/5 [1 PR, 2 CR]) vs 40% (2/5 [2 CR]). Ruxolitinib (n=4; 2 CRs, 1 PR), methotrexate (n=1; 1 CR) and lenalidomide (n=1; 1 CR) were also used in R/R cpPTCL-NOS.
For cpPTCL-NOS and cnPTCL-NOS cohorts, 2-yr and 5-yr OS were 63.4% (26/41) vs 52.6% (20/38) (p=0.37) and 39.4% (13/33) and 16.7% (5/30) (p=0.06). For IPI scores of 0-3, 2-yr and 5-yr OS were 80% (24/30) vs 64.5% (20/31) (p=0.25) and 54.5% (12/22) vs 21.7% (5/23) (p=0.03). Among cpPTCL-NOS pts, comparing low Ki67 to high Ki67, 2-yr and 5-yr OS were 92.9% (13/14) vs 48.1% (12/28) (p<0.01) and 75% (6/8) vs 28% (7/25) (p<0.04). When comparing low Ki67 pts between cpPTCL-NOS and cnPTCL-NOS cohorts, 2-yr and 5-yr OS were 92.9% (13/14) vs 50% (4/8) (p<0.04) and 75% (6/8) vs 12.5% (1/8) (p<0.05). In exploratory multivariable Cox proportional hazards regression adjusting for age, IPI >3, and elevated LDH, cpPTCL-NOS/low Ki-67 represented the subgroup with the most favorable OS. Compared with this reference group, cnPTCL-NOS/low Ki-67 remained independently associated with inferior OS (adjusted HR 4.25, 95% CI 1.04–17.33; p<0.05), while cpPTCL-NOS/high Ki-67 and cnPTCL-NOS/high Ki-67 demonstrated higher mortality risks that did not reach statistical significance.
CONCLUSIONS: Of evaluable pts, 51% of the PTCL-NOS pts were cpPTCL-NOS. The cpPTCL-NOS cohort had a significantly higher proportion of pts developing lymphoma associated-HLH and pts having a synchronous/ metachronous B-cell malignancy. cpPTCL-NOS pts had a high proportion of TET2, DNMT3A and STAT3 DAVs. cpPTCL-NOS/low Ki67 pts had significantly better OS compared to other subgroups of pts, notably cnPTCL-NOS/low Ki67. A better understanding of cpPTCL-NOS biology and outcomes is needed, notably for the unique cohort of indolent, low Ki67, cpPTCL-NOS pts.
DISCLOSURES
Colin J. Thomas, MD: Kyowa Kirin - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony); Electra Therapeutics - Consultancy (Includes expert testimony)